Tobacco.org

• Nabi Biopharmaceuticals Reports Encouraging Preliminary Results Of NicVAX(TM) Clinical Trial 

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced preliminary results of a phase I safety and immunogenicity trial of NicVAX(TM) (Nicotine Conjugate Vaccine), an investigational nicotine conjugate vaccine, in 20 healthy volunteers. Although the study blind remains in effect, analysis of blood samples from the participants receiving NicVAX shows that a single dose of NicVAX resulted in a rapid immune response and generated substantial amounts of nicotine specific antibodies. Local reactions to vaccination were mild to moderate, temporary and required no therapeutic intervention. Antibody levels were detected within 7 days of vaccination and were maintained or continued to increase through 60 days post-vaccination.

"While this trial remains ongoing in order to maximize the safety data collected, we are pleased to note the ability of NicVAX to rapidly stimulate the formation of sustained levels of nicotine-specific antibodies in vaccinated individuals," stated David J. Gury, chairman, president, and chief executive officer of Nabi Biopharmaceuticals.

Jump to full article »